Explore
Systemic Autoinflammatory Diseases—Clinical Rheumatic Challenges
Eugen Feist (editor)
2021
0 Ungluers have
Faved this Work
Login to Fave
Autoinflammation, as a relatively new field in clinical rheumatology, has gained an increasing importance in recent years. The number of identified entities and affected patients has gradually increased, and some of the involved pathways have already been identified. This progress allows a deeper understanding of closely linked diseases, namely, inflammasomopathies, interferonopathies, Relo-pathies, and proteasome associated syndromes. These insights have not only improved their classification but also helped to identify new treatment targets of pro-inflammatory cytokines, including IL-1ß, IL-6, interferon-, and TNF-alpha. Nevertheless, there is still a high medical need, especially in reliable outcome measures, for confirmation of data from controlled clinical trials and, finally, also for long-term experience from registers. This issue welcomes all types of papers on the broad spectrum of clinical characteristics, prognosis, pathophysiology, and treatment of autoinflammatory diseases. The goal of this Special Issue is to further raise awareness of autoinflammatory processes and to better separate them from well-established autoimmune diseases. It is clear that we have entered a new age in this complex field, linking rheumatology even closer to immunology.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 68 times via unglue.it ebook links.
- 68 - pdf (CC BY) at Unglue.it.
Keywords
- adult-onset Still’s disease
- anakinra
- anti-IL-1 treatment
- Arthritis
- ASAS classification criteria
- aspiration
- autoimmune
- Autoinflammation
- autoinflammatory disease
- autoinflammatory diseases
- autoinflammatory disorder
- canakinumab
- CAPS
- CINCA
- clinical management
- colchicine
- Computed tomography (CT)
- Coronavirus
- Cytokines
- damage index
- diagnostic delay
- DNA damage repair
- dysphagia
- edema
- FCAS
- febuxostat
- FMF
- genetic inheritance
- gout
- haemophagocytic lymphohistiocytosis
- hearing loss
- hepatotoxicity
- Hounsfield unit
- human leukocyte antigen
- IFN-γ
- IL-1 inhibitors
- imaging
- immunoglobulin G4-related orbital disease (IgG4-ROD)
- Inflammation
- inflammatory idiopathic myopathy
- Interleukin-1
- JAK inhibitor
- macrophage activation syndrome
- medicine
- monogenic autoinflammatory syndrome
- MWS
- myositis
- n/a
- Neoplasms
- new genetic variant
- NGS
- NOMID
- orbital lymphoma (OL)
- PBMCS
- personalized therapy
- Pneumonia
- proliferation
- prophylaxis
- proteasome
- proteasome-associated autoinflammatory syndrome
- Rheumatoid arthritis
- SARS-CoV-2 antibody response
- spondyloarthritis
- surf
- synovitis
- systemic-onset juvenile idiopathic arthritis
- T lymphocytes
- Therapy
- undifferentiated enthesitis and/or arthritis
- urticarial-like rash
- γH2AX
Links
DOI: 10.3390/books978-3-0365-2561-7Editions